Aure Aflalo

Aure Aflalo

Auto-generated profile, based on publicly available information

Aure Aflalo

Centre for Immuno-Oncology, University of Oxford 2 Nuffield Department of Clinical Medicine Oxford

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2021 in International Journal of Immunogenetics
Verified
Journal Article
Open access
PDF file
AAAure Aflalo
Aure Aflalo
LBLouise H. Boyle
Louise H. Boyle
MHC class I (MHC‐I) molecules undergo an intricate folding process in order to pick up antigenic peptide to present to the immune system. In recent years, the discovery of a new peptide editor for MHC‐I has added an extra level of complexity in our understanding of how peptide presentation is regulated. On top of this, the incredible diversity in MHC‐I molecules leads to significant variation in the interaction between MHC‐I and components of the antigen processing and presentation pathway. Here, we review our current understanding regarding how polymorphisms in human leukocyte antigen class I molecules influence their interactions with key components of the antigen processing and presentation pathway. A deeper understanding of this may offer new insights regarding how apparently subtle variation in MHC‐I can have a significant impact on susceptibility to disease.

21 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
ANAndreas Neerincx
Andreas Neerincx
AAAure Aflalo
Aure Aflalo
IHIda Hafstrand
Ida Hafstrand
ATAlice Torres
Alice Torres
AMAlison McDowall
Alison McDowall
LBLouise Boyle
Louise Boyle
Low tumour immunogenicity is a major hurdle to overcome in the treatment of cancers with immunotherapies. Here, we reveal a novel therapeutic approach to increase tumour immunogenicity. By delivering the major histocompatibility complex class I (MHC-I) peptide exchange catalyst TAPBPR in an antibody-mediated manner onto the plasma membrane of tumour cells, extracellular MHC-I become highly peptide-receptive. Upon exposure to low doses of exogenous peptide, MHC-I molecules on tumour cells are efficiently loaded with immunogenic antigens, including those derived from human cytomegalovirus and Epstein-Barr virus. TAPBPR-antibody fusion proteins were delivered specifically to tumours in vivo. Finally, antigen-specific CD8+ T cells respond to tumour cells in a targeted manner and can mediate killing of antibody target-positive cells. As memory T cells specific for previously encountered common viruses patrol tumours, TAPBPR-based therapeutics could offer an attractive means to redirected virus-specific T cells against tumours in the fight against cancer.

6 November 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
TCTakayuki Chikata
Takayuki Chikata
KKKimiko Kuroki
Kimiko Kuroki
NKNozomi Kuse
Nozomi Kuse
AKAnna E. Kliszczak
Anna E. Kliszczak
WPWayne Paes
Wayne Paes
MTMasafumi Takiguchi
Masafumi Takiguchi
NK cells and CD8+ T cells both contribute to HIV-1 control. These cells not only suppress HIV-1 replication, but also select HIV-1 escape mutant viruses. Most viruses bearing T cell escape mutations are expected to remain susceptible to NK cell suppression, but their inhibition by NK cells is unclear. We investigated the role of HIV-1-specific CD8+ T cells and NK cells recognizing superimposed Pol peptides in selection and control of HIV-1 mutant virus. KIR2DL2+NK cells have an enhanced ability to recognize HIV-1-infected cells after selection of Pol mutant virus by PolIY11-specific HLA-C*12:02-restricted T cells. Mass spectrometry-based immunopeptidome profiling of HIV-1-infected cells and analysis of crystal structures of TCR- and KIR2DL2-HLA-C*12:02-peptide complexes demonstrate the molecular basis for selection and recognition of the escape mutant epitope by TCR and KIR2DL2. The present study elucidates the mechanism for selection and inhibition of an HIV-1 escape virus by T cells and NK cells.

4 August 2026 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MBMelibea Berzosa
Melibea Berzosa
AMAdam N. McShane
Adam N. McShane
AKAnna E. Kliszczak
Anna E. Kliszczak
AAAure Aflalo
Aure Aflalo
PNPratiti Nanda
Pratiti Nanda
DMDessislava Malinova
Dessislava Malinova
A high-affinity antibody response to both infection and vaccination critically relies on the ability of B cells to capture and process antigen for presentation to CD4+ T cells. The cellular processes from antigen recognition to full B cell activation require a finely orchestrated series of events, involving signalling and intracellular trafficking mechanisms. Here, we describe a novel regulator of B cell receptor (BCR) endocytosis and intracellular trafficking. Multidomain trafficking protein sorting-related receptor with A-type repeats (SorLA) associates with the BCR and regulates uptake of both soluble and substrate-bound antigens. SorLA deletion results in altered BCR–antigen intracellular trafficking to degradative compartments, modulating eventual antigen presentation. Crucially, this change in antigen trafficking results in a significant reduction in plasma cells and humoral responses in vivo. Given the critical importance of antigen presentation in immunity, as well as autoimmune disease and malignancy, these results identify a new cellular pathway in B cell biology with potential implications for immune regulation.